# Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

> **NCT00977665** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 174 (actual)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** rasagiline mesylate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00977665
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2015-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977665, "Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00977665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*